Organisation paid for research Program year 2025 Source: CMS Open Payments

Philadelphia Fight

Neither a doctor nor a teaching hospital

Research payments

$761,210

195 payments

Through program year 2025, Philadelphia Fight is reported as receiving $761,210 in research payments, across 195 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $80,465 17
2024 Research $73,599 16
2023 Research $83,278 22
2022 Research $108,600 22
2021 Research $104,149 29
2020 Research $146,761 37
2019 Research $164,358 52

Breakdown

Who paid Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $606,789 141 payments
  2. Janssen Research & Development, LLC $76,421 31 payments
  3. ViiV Healthcare Company $54,108 20 payments
  4. Merck Sharp & Dohme Corporation $13,000 2 payments
  5. AbbVie, Inc. $10,892 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Captivate (Cab la for Prep Utilization Outcomes Experience) $26,131 2 payments
  2. A Phase 4 Randomized Active Controlled Open label Study to Evaluate the Safety and Tolerability of Switching to Once Daily Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Fixed dose Combination FDC Regimen in Virologically suppressed Human $24,298 11 payments
  3. A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People at least 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $23,068 1 payment
  4. A Phase 4 Randomized Active Controlled Open label Study to Evaluate the Safety and Tolerability of Switching to Once Daily Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Fixed dose Combination FDC Regimen in Virologically suppressed Human Immunodeficiency Virus Type 1 HIV1 Infected Participants Experiencing Rapid Weight Gain with an INI + TAFFTC ARV Regimen $22,086 11 payments
  5. A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Regimen in Virologicallysuppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain with an INI + TAF/FTC ARV Regimen $21,737 5 payments
  6. A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $21,098 14 payments
  7. A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection $17,377 1 payment
  8. A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $13,957 1 payment
  9. A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $13,077 1 payment
  10. A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People at least 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $12,267 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record